Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease

被引:22
作者
Bateman, Randall J. [1 ]
Klunk, William E. [2 ]
机构
[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA
关键词
Alzheimer's disease; Alzheimer; treatment; biomarker; amyloid; amyloid-beta; CSF; cerebrospinal fluid; therapeutic; kinetics; production; clearance; PET; PiB;
D O I
10.1016/j.nurt.2008.05.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease (AD) is the most common cause of dementia and is an increasing public health problem. Because of the severity and increasing prevalence of the disease in the population, it is urgent that better treatments be developed. Active research efforts over the past several decades have produced a vast knowledge base regarding AD natural history, pathology, and key biological mediators involved in pathogenesis. As knowledge of the biomolecular mechanisms of AD has increased over the past several decades, there has been a growing consensus on the pathophysiology of the disease. These scientific advancements have led to proposals for disease-modifying therapeutic interventions that promise to significantly alter the course of AD. The translation from preclinical models to human studies requires therapeutic biomarkers to increase the likelihood of success. This review covers the current methods and technologies used in the therapeutic translation of proposed disease-modifying therapies for AD.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 105 条
[31]   β-secretase protein and activity are increased in the neocortex in Alzheimer disease [J].
Fukumoto, H ;
Cheung, BS ;
Hyman, BT ;
Irizarry, MC .
ARCHIVES OF NEUROLOGY, 2002, 59 (09) :1381-1389
[32]   Age but not diagnosis is the main predictor of plasma amyloid β-protein levels [J].
Fukumoto, H ;
Tennis, M ;
Locascio, JJ ;
Hyman, BT ;
Growdon, JH ;
Irizarry, MC .
ARCHIVES OF NEUROLOGY, 2003, 60 (07) :958-964
[33]   High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].
Galasko, D ;
Chang, L ;
Motter, R ;
Clark, CM ;
Kaye, J ;
Knopman, D ;
Thomas, R ;
Kholodenko, D ;
Schenk, D ;
Lieberburg, I ;
Miller, B ;
Green, R ;
Basherad, R ;
Kertiles, L ;
Boss, MA ;
Seubert, P .
ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945
[34]   ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN [J].
GAMES, D ;
ADAMS, D ;
ALESSANDRINI, R ;
BARBOUR, R ;
BERTHELETTE, P ;
BLACKWELL, C ;
CARR, T ;
CLEMENS, J ;
DONALDSON, T ;
GILLESPIE, F ;
GUIDO, T ;
HAGOPIAN, S ;
JOHNSONWOOD, K ;
KHAN, K ;
LEE, M ;
LEIBOWITZ, P ;
LIEBERBURG, I ;
LITTLE, S ;
MASLIAH, E ;
MCCONLOGUE, L ;
MONTOYAZAVALA, M ;
MUCKE, L ;
PAGANINI, L ;
PENNIMAN, E ;
POWER, M ;
SCHENK, D ;
SEUBERT, P ;
SNYDER, B ;
SORIANO, F ;
TAN, H ;
VITALE, J ;
WADSWORTH, S ;
WOLOZIN, B ;
ZHAO, J .
NATURE, 1995, 373 (6514) :523-527
[35]  
Games D, 2006, J ALZHEIMERS DIS, V9, P133
[36]   ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J].
GLENNER, GG ;
WONG, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) :885-890
[37]   SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE [J].
GOATE, A ;
CHARTIERHARLIN, MC ;
MULLAN, M ;
BROWN, J ;
CRAWFORD, F ;
FIDANI, L ;
GIUFFRA, L ;
HAYNES, A ;
IRVING, N ;
JAMES, L ;
MANT, R ;
NEWTON, P ;
ROOKE, K ;
ROQUES, P ;
TALBOT, C ;
PERICAKVANCE, M ;
ROSES, A ;
WILLIAMSON, R ;
ROSSOR, M ;
OWEN, M ;
HARDY, J .
NATURE, 1991, 349 (6311) :704-706
[38]   A century of Alzheimer's disease [J].
Goedert, Michel ;
Spillantini, Maria Grazia .
SCIENCE, 2006, 314 (5800) :777-781
[39]   PRODUCTION OF AMYLOID-BETA PROTEIN FROM NORMAL AMYLOID BETA-PROTEIN PRECURSOR (BETA-APP) AND THE MUTATED BETA-APPS LINKED TO FAMILIAL ALZHEIMERS-DISEASE [J].
GOLDE, TE ;
CAI, XD ;
SHOJI, M ;
YOUNKIN, SG .
ALZHEIMERS DISEASE: AMYLOID PRECUSOR PROTEINS, SIGNAL TRANSDUCTION, AND NEURONAL TRANSPLANTATION, 1993, 695 :103-108
[40]   Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease [J].
Graff-Radford, Neill R. ;
Crook, Julia E. ;
Lucas, John ;
Boeve, Bradley F. ;
Knopman, David S. ;
Ivnik, Robert J. ;
Smith, Glenn E. ;
Younkin, Linda H. ;
Petersen, Ronald C. ;
Younkin, Steven G. .
ARCHIVES OF NEUROLOGY, 2007, 64 (03) :354-362